Recombinant human activated protein C for the postexposure treatment of ebola hemorrhagic fever

Lisa E. Hensley, Edward L. Stevens, S. Betty Yan, Joan B. Geisbert, William L. Macias, Tom Larsen, Kathleen M. Daddario-DiCaprio, Gail H. Cassell, Peter B. Jahrling, Thomas Geisbert

Research output: Contribution to journalArticle

120 Citations (Scopus)

Abstract

Background. Infection of primates with Zaire ebolavirus (ZEBOV) leads to hypotension, coagulation disorders, and an impaired immune response and, in many ways, resembles severe sepsis. Rapid decreases in plasma levels of protein C are a prominent feature of severe sepsis and ZEBOV hemorrhagic fever (ZHF). Currently, recombinant human activated protein C (rhAPC [Xigris; Eli Lilly]) is licensed for treating human patients with severe sepsis who are at high risk of death. The aim of this study was to test the efficacy of rhAPC as a potential treatment for ZHF. Methods. Fourteen rhesus macaques were challenged with a uniformly lethal dose of ZEBOV; 11 of these monkeys were treated by intravenous infusion with rhAPC beginning 30-60 min after challenge and continuing for 7 days. Three control monkeys received sterile saline in parallel. Results. All 3 control monkeys died on day 8, whereas 2 of the 11 rhAPC-treated monkeys survived. The mean time to death for the rhAPC-treated monkeys that did not survive ZEBOV challenge was 12.6 days. The difference in survival was significant when the rhAPC-treated monkeys were compared with historical controls. Conclusions. The experimental findings provide evidence that ZHF and severe sepsis share underlying mechanisms and may respond to the same therapies.

Original languageEnglish (US)
JournalJournal of Infectious Diseases
Volume196
Issue numberSUPPL. 2
DOIs
StatePublished - Nov 15 2007
Externally publishedYes

Fingerprint

Ebola Hemorrhagic Fever
Protein C
Ebolavirus
Haplorhini
Democratic Republic of the Congo
Sepsis
Fever
Therapeutics
Immune System Diseases
drotrecogin alfa activated
Macaca mulatta
Intravenous Infusions
Hypotension
Primates
Blood Proteins
Survival

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health
  • Immunology

Cite this

Recombinant human activated protein C for the postexposure treatment of ebola hemorrhagic fever. / Hensley, Lisa E.; Stevens, Edward L.; Yan, S. Betty; Geisbert, Joan B.; Macias, William L.; Larsen, Tom; Daddario-DiCaprio, Kathleen M.; Cassell, Gail H.; Jahrling, Peter B.; Geisbert, Thomas.

In: Journal of Infectious Diseases, Vol. 196, No. SUPPL. 2, 15.11.2007.

Research output: Contribution to journalArticle

Hensley, LE, Stevens, EL, Yan, SB, Geisbert, JB, Macias, WL, Larsen, T, Daddario-DiCaprio, KM, Cassell, GH, Jahrling, PB & Geisbert, T 2007, 'Recombinant human activated protein C for the postexposure treatment of ebola hemorrhagic fever', Journal of Infectious Diseases, vol. 196, no. SUPPL. 2. https://doi.org/10.1086/520598
Hensley, Lisa E. ; Stevens, Edward L. ; Yan, S. Betty ; Geisbert, Joan B. ; Macias, William L. ; Larsen, Tom ; Daddario-DiCaprio, Kathleen M. ; Cassell, Gail H. ; Jahrling, Peter B. ; Geisbert, Thomas. / Recombinant human activated protein C for the postexposure treatment of ebola hemorrhagic fever. In: Journal of Infectious Diseases. 2007 ; Vol. 196, No. SUPPL. 2.
@article{eab56891ce9044b1b1fbe1bfaa259f5f,
title = "Recombinant human activated protein C for the postexposure treatment of ebola hemorrhagic fever",
abstract = "Background. Infection of primates with Zaire ebolavirus (ZEBOV) leads to hypotension, coagulation disorders, and an impaired immune response and, in many ways, resembles severe sepsis. Rapid decreases in plasma levels of protein C are a prominent feature of severe sepsis and ZEBOV hemorrhagic fever (ZHF). Currently, recombinant human activated protein C (rhAPC [Xigris; Eli Lilly]) is licensed for treating human patients with severe sepsis who are at high risk of death. The aim of this study was to test the efficacy of rhAPC as a potential treatment for ZHF. Methods. Fourteen rhesus macaques were challenged with a uniformly lethal dose of ZEBOV; 11 of these monkeys were treated by intravenous infusion with rhAPC beginning 30-60 min after challenge and continuing for 7 days. Three control monkeys received sterile saline in parallel. Results. All 3 control monkeys died on day 8, whereas 2 of the 11 rhAPC-treated monkeys survived. The mean time to death for the rhAPC-treated monkeys that did not survive ZEBOV challenge was 12.6 days. The difference in survival was significant when the rhAPC-treated monkeys were compared with historical controls. Conclusions. The experimental findings provide evidence that ZHF and severe sepsis share underlying mechanisms and may respond to the same therapies.",
author = "Hensley, {Lisa E.} and Stevens, {Edward L.} and Yan, {S. Betty} and Geisbert, {Joan B.} and Macias, {William L.} and Tom Larsen and Daddario-DiCaprio, {Kathleen M.} and Cassell, {Gail H.} and Jahrling, {Peter B.} and Thomas Geisbert",
year = "2007",
month = "11",
day = "15",
doi = "10.1086/520598",
language = "English (US)",
volume = "196",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "SUPPL. 2",

}

TY - JOUR

T1 - Recombinant human activated protein C for the postexposure treatment of ebola hemorrhagic fever

AU - Hensley, Lisa E.

AU - Stevens, Edward L.

AU - Yan, S. Betty

AU - Geisbert, Joan B.

AU - Macias, William L.

AU - Larsen, Tom

AU - Daddario-DiCaprio, Kathleen M.

AU - Cassell, Gail H.

AU - Jahrling, Peter B.

AU - Geisbert, Thomas

PY - 2007/11/15

Y1 - 2007/11/15

N2 - Background. Infection of primates with Zaire ebolavirus (ZEBOV) leads to hypotension, coagulation disorders, and an impaired immune response and, in many ways, resembles severe sepsis. Rapid decreases in plasma levels of protein C are a prominent feature of severe sepsis and ZEBOV hemorrhagic fever (ZHF). Currently, recombinant human activated protein C (rhAPC [Xigris; Eli Lilly]) is licensed for treating human patients with severe sepsis who are at high risk of death. The aim of this study was to test the efficacy of rhAPC as a potential treatment for ZHF. Methods. Fourteen rhesus macaques were challenged with a uniformly lethal dose of ZEBOV; 11 of these monkeys were treated by intravenous infusion with rhAPC beginning 30-60 min after challenge and continuing for 7 days. Three control monkeys received sterile saline in parallel. Results. All 3 control monkeys died on day 8, whereas 2 of the 11 rhAPC-treated monkeys survived. The mean time to death for the rhAPC-treated monkeys that did not survive ZEBOV challenge was 12.6 days. The difference in survival was significant when the rhAPC-treated monkeys were compared with historical controls. Conclusions. The experimental findings provide evidence that ZHF and severe sepsis share underlying mechanisms and may respond to the same therapies.

AB - Background. Infection of primates with Zaire ebolavirus (ZEBOV) leads to hypotension, coagulation disorders, and an impaired immune response and, in many ways, resembles severe sepsis. Rapid decreases in plasma levels of protein C are a prominent feature of severe sepsis and ZEBOV hemorrhagic fever (ZHF). Currently, recombinant human activated protein C (rhAPC [Xigris; Eli Lilly]) is licensed for treating human patients with severe sepsis who are at high risk of death. The aim of this study was to test the efficacy of rhAPC as a potential treatment for ZHF. Methods. Fourteen rhesus macaques were challenged with a uniformly lethal dose of ZEBOV; 11 of these monkeys were treated by intravenous infusion with rhAPC beginning 30-60 min after challenge and continuing for 7 days. Three control monkeys received sterile saline in parallel. Results. All 3 control monkeys died on day 8, whereas 2 of the 11 rhAPC-treated monkeys survived. The mean time to death for the rhAPC-treated monkeys that did not survive ZEBOV challenge was 12.6 days. The difference in survival was significant when the rhAPC-treated monkeys were compared with historical controls. Conclusions. The experimental findings provide evidence that ZHF and severe sepsis share underlying mechanisms and may respond to the same therapies.

UR - http://www.scopus.com/inward/record.url?scp=38449092257&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38449092257&partnerID=8YFLogxK

U2 - 10.1086/520598

DO - 10.1086/520598

M3 - Article

VL - 196

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - SUPPL. 2

ER -